TY - JOUR
T1 - Epidemiological differences among pneumococcal serotypes
AU - Hausdorff, William P.
AU - Feikin, Daniel R.
AU - Klugman, Keith P.
N1 - Funding Information:
WPH is a full-time employee of GlaxoSmithKline Biologicals, which has a pneumococcal conjugate vaccine development programme; DRF reports no conflicts; KPK has received consulting fees, lecture fees, and grant support from Wyeth and consulting fees from Aventis Pasteur and GlaxoSmithKline Biologicals, each of which have pneumococcal conjugate vaccine development programmes.
PY - 2005/2/1
Y1 - 2005/2/1
N2 - The bacterial species Streptococcus pneumoniae consists of 90 immunologically distinct serotypes, of which some possess distinct epidemiological properties. Certain serotypes are much more likely to be associated with nasopharyngeal colonisation than to cause invasive disease. Compared with transient or infrequent colonisers, serotypes carried at high rates by young children may rapidly elicit age-associated natural immunity to invasive disease. Other serotypes seem to be of disproportionate importance as causes of disease in very young infants, in older children, in immunocompromised individuals, or in elderly people. Some serotypes seem to be associated with particular disease syndromes, such as complicated pneumonias in children, or with higher rates of hospitalisation in children or mortality in adults, or are consistently responsible for outbreaks in certain populations. Since pneumococcal conjugate vaccines are directed at specific serotypes, national immunisation advisory committees may wish to consider these serotype-specific properties when considering which vaccine formulation to introduce into a national programme.
AB - The bacterial species Streptococcus pneumoniae consists of 90 immunologically distinct serotypes, of which some possess distinct epidemiological properties. Certain serotypes are much more likely to be associated with nasopharyngeal colonisation than to cause invasive disease. Compared with transient or infrequent colonisers, serotypes carried at high rates by young children may rapidly elicit age-associated natural immunity to invasive disease. Other serotypes seem to be of disproportionate importance as causes of disease in very young infants, in older children, in immunocompromised individuals, or in elderly people. Some serotypes seem to be associated with particular disease syndromes, such as complicated pneumonias in children, or with higher rates of hospitalisation in children or mortality in adults, or are consistently responsible for outbreaks in certain populations. Since pneumococcal conjugate vaccines are directed at specific serotypes, national immunisation advisory committees may wish to consider these serotype-specific properties when considering which vaccine formulation to introduce into a national programme.
UR - http://www.scopus.com/inward/record.url?scp=12944326295&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=12944326295&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(05)70083-9
DO - 10.1016/S1473-3099(05)70083-9
M3 - Review article
C2 - 15680778
AN - SCOPUS:12944326295
SN - 1473-3099
VL - 5
SP - 83
EP - 93
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 2
ER -